Remedium Bio announces publication of preclinical data demonstrating the safety and chondrogenic activity of RMD1101 in Cartilage

BOSTON, March 13, 2023 /PRNewswire/ — Remedium Bio, a gene therapy company developing novel treatments for significant unmet needs, today announced the publication of pre-clinical data demonstrating the safety and chondrogenic activity of RMD1101, its innovative gene therapy for…

Leave a Reply

Your email address will not be published. Required fields are marked *